论文部分内容阅读
目的比较国产氯吡格雷与进口氯吡格雷在非S-T段抬高型心肌梗死介入治疗中的疗效及安全性。方法130例非S-T段抬高型心肌梗死患者,随机分为两组,泰嘉组:63例,泰嘉600mg起始量,之后75mg/d,维持一年;波立维组:67例,波立维600mg起始量,之后75mg/d,维持一年。观察病变特征、心血管事件和出血、药物不良反应等指标。结果泰嘉组在心血管事件与出血、药物不良反应与波立维组差异无统计学意义(P>0.05)。结论泰嘉与波立维在非S-T段抬高型心肌梗死PCI治疗同样安全、有效,但泰嘉效价比较波立维为高,更适合我国广泛应用。
Objective To compare the efficacy and safety of domestic clopidogrel with imported clopidogrel in interventional therapy of non-S-T elevation myocardial infarction. Methods A total of 130 patients with non-ST-elevation myocardial infarction were randomly divided into two groups: 63 patients in the Taijia group and 600mg in the Taijia group, followed by 75mg / d for one year. In the Bolivian group, 67 patients Victoria 600mg initial volume, then 75mg / d, to maintain a year. Observe the pathological features, cardiovascular events and bleeding, adverse drug reactions and other indicators. Results There was no significant difference in the incidence of cardiovascular events and bleeding, adverse drug reactions between the Taijia group and the bolivian group (P> 0.05). Conclusion Taijia and Bolivian in the non-S-T segment elevation myocardial infarction PCI treatment is equally safe and effective, but the Thai tiger potency compared with wave dimension is high, more suitable for our wide range of applications.